Calidi to Present New Data on CLD-401 at the 2025 SITC Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
New Data Presentation: Calidi Biotherapeutics presented new data on its therapeutic candidate CLD-401 from the RedTail platform at the SITC Annual Meeting.
IND-Enabling Studies: The company is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug application by the end of 2026.
Strategic Partnerships: Calidi is actively seeking strategic partnerships to enhance clinical development and expand the impact of its RedTail platform.
Future Prospects: The anticipated IND application and partnerships aim to accelerate the development of CLD-401 and its potential applications in cancer treatment.
Analyst Views on CLDI
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
